BioCentury | May 4, 2020

Stemline takeout gives Menarini U.S. oncology beachhead

Although Menarini will gain a modest-selling drug by acquiring Stemline for up to $677 million, the Italian biopharma will also establish a U.S. oncology presence as its cancer pipeline matures. The deal gives Menarini Group...
BioCentury | Apr 14, 2020

Expanded deal with Kyowa could give MEI cash through drug approval

Building on a 2018 deal in Japan, MEI Pharma granted Kyowa Kirin ex-U.S. rights to its PI3Kδ inhibitor ME-401 in an expanded partnership that could shore up the San Diego-based biotech’s balance sheet through a...
BioCentury | Mar 26, 2020

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

...investors. The biotech plans to start this year a Phase II study of its lead HDAC6...
...Targets BCMA (TNFRSF17; CD269) - Tumor necrosis factor receptor superfamily member 17 HDAC6 - Histone deacetylase 6 BioCentury...
BioCentury | Mar 20, 2020
Emerging Company Profile

Eikonizo: brain-penetrant HDAC inhibitors for neurodegeneration's lead program is an oral small molecule that penetrates the blood-brain barrier and inhibits HDAC6... image HDAC6 in human brains, which the company can use to quantify how much HDAC6...
...None issued Targets HDAC6 - Histone deacetylase 6 SOD1 - Superoxide dismutase 1 Elizabeth S. Eaton, Staff Writer Histone deacetylase 6 (HDAC6) blood-brain...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BioCentury | Jan 30, 2020
Distillery Therapeutics

HDAC3 identified as obesity target

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity Intestinal HDAC3 inhibition could treat obesity. In mice fed a normal diet, intestinal knockout of HDAC3 increased intestinal expression of lipid metabolism genes. In a mouse model of obesity induced...
BioCentury | Dec 12, 2019

HDAC9 identified as target in atherosclerosis

DISEASE CATEGORY: Cardiovascular INDICATION: Atherosclerosis Inhibiting HDAC9 could treat atherosclerosis by reducing vascular calcification, one of the disease's hallmarks. Six SNPs for which HDAC9 is the nearest gene were associated with abdominal aortic calcification in...
BioCentury | Dec 2, 2019
Company News

Dec. 2 Regulatory Roundup: Chipscreen’s approval; plus Priority Review for new Imfinzi, Keytruda indications; EMA reviewing Orchard, Amarin candidates; and more

A spate of regulatory news since the start of the Thanksgiving holiday included a drug approval for Chipscreen, a duo of Priority Reviews from FDA, a pair of EMA reviews, and the scheduling of two...
BioCentury | Nov 21, 2019

Entinostat-derived LSD1 and HDAC dual inhibitor for pediatric glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer An HDAC and LSD1 inhibitor could treat diffuse intrinsic pontine glioma, a subtype of pediatric brain cancer. A dual HDAC and LSD1 inhibitor tool compound, derived from the HDAC...
BioCentury | Nov 19, 2019
Company News

Alkermes expands CNS pipeline with Rodin acquisition

A mix of preclinical and clinical data spurred Alkermes' takeout of Rodin, which adds HDAC-targeting programs to the biotech's CNS arsenal. The deal comes less than a month after Alkermes plc (NASDAQ:ALKS) restructured to maintain...
Items per page:
1 - 10 of 1042